This page is updated frequently with new Omeprazole-related patent applications.
|| List of recent Omeprazole-related patents
|Method for treating a patient at risk for developing an nsaid-associated ulcer|
The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an nsaid-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.. .
Horizon Pharma Usa, Inc.
|Novel producing metabolites from omeprazole using bacterial cytochrome p450, and composition for same|
The present invention relates to a novel method for producing metabolites from omeprazole using bacterial cytochrome p450, and a composition therefor, and more specifically, to a composition and a kit for producing a 5′-hydroxyl product from omeprazole, containing bacterial cytochrome p450 bm3 (cyp102a1) or mutants thereof, and to a method for producing the same. The composition, the kit, and the method are capable of economically and highly efficiently mass-producing the 5′-hydroxyl product from the omeprazole, and thus will significantly contribute to development of a novel drug using metabolites from the omeprazole..
|Controlled dosing of clopidogrel with gastric acid inhibition therapies|
The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (ppi) and optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other.
|Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof|
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on omeprazole therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .
Amarin Pharmaceuticals Ireland Limited
|Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same|
The present disclosure relates to pharmaceutical compositions comprising omeprazole, lansoprazole and sodium bicarbonate. Methods of using such compositions are also provided.
The Curators Of The University Of Missouri
|Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid|
The present invention is directed to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a gastrointestinal disorder or disease, or the symptoms associated with, or related to a gastrointestinal disorder or disease in a subject in need thereof. In one aspect, the present invention provides a pharmaceutical composition comprising a proton pump inhibiting agent and a buffering agent for oral administration and ingestion by a subject.
|Compositions and methods for delivery of omeprazole plus acetylsalicylic acid|
The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.. .
|Liquid dosage form and delivery system|
A pharmaceutical dosage form comprising solid liquid components comprising solid and liquid components; the solid component comprising omeprazole as active ingredient; one or more water soluble excipients; wherein the liquid component comprises: a surfactant; water and optional further excipients.. .
|Pharmaceutical composition of omeprazole|
The present invention refers to oral solid pharmaceutical compositions comprising concentrate omeprazole pellets, processes for the preparation of the same and their use as medicaments, more particularly for the treatment and/or prophylaxis of a gastrointestinal disorder.. .
|Process for the resolution of omeprazole|
The present invention relates to process for the resolution of omeprazole. The present invention further provides a novel compound of enantiomers of omeprazole cyclic amine salt and a process for preparing it.
Crystalline s-omeprazole strontium hydrate, preparing same, and pharmaceutical composition containing same
Disclosed are a crystalline s-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, thermostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.. .
Process for the preparation of esomeprazole magnesium dihydrate
A process for preparing form a of (s)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole magnesium dihydrate, processes for preparing various intermediates useful in the preparation of form a of (s)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole magnesium dihydrate and a novel polymorphic form ii of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]thio]-1h-benzimidazole.. .
Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals: oxidation of coordinated benzimidazole to omeprazole
The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1h-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl) methylsulfinyl)-1h-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to the sulfoxide commonly known as omeprazole and wherein one of either the r and s enantiomers is formed to an enantiomeric excess.. .
Pharmaceutical compositions of nsaid and acid inhibitor
The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising esomeprazole and naproxen and a process for preparation thereof.
Omeprazole topics: Omeprazole, Esomeprazole, Esomeprazole Magnesium Dihydrate, Benzimidazole, Someprazole, Esomeprazole Magnesium, Omeprazole Magnesium, Polymorphic, Organic Molecules, S Omeprazole, Organic Molecule, Enantiomer, Lansoprazole
Follow us on Twitter
This listing is a sample listing of patent applications related to Omeprazole for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Omeprazole with additional patents listed. Browse our RSS directory or Search for other possible listings.